No Data
No Data
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
UroGen Pharma Is Maintained at Neutral by Goldman Sachs
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Scotiabank Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $23
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Cuts Target Price to $16
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday